CC
KNSA icon

Corton Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Corton Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,146
Closed -$378K – 509
2024
Q3 		$378K Buy
+15,146
New +$369K 0.18% 121

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Corton Capital's KNSA Position: Q4 2024 in Review

Corton Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 15,146 shares — an estimated $378K sold.

Corton Capital first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $378K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Corton Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Corton Capital sold 15,146 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $378K.
  • Corton Capital first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Corton Capital's Kiniksa Pharmaceuticals position peaked at $378K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Corton Capital's 13F filing for Q4 2024, filed 14 Feb 2025.